Antioxidant Approaches to Alzheimer's Disease Therapy
阿尔茨海默病治疗的抗氧化方法
基本信息
- 批准号:7229871
- 负责人:
- 金额:$ 16.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-15 至 2008-01-31
- 项目状态:已结题
- 来源:
- 关键词:3-nitrotyrosineAlzheimer&aposs DiseaseAmyloid beta-ProteinAmyloid depositionAmyotrophic Lateral SclerosisAntioxidantsAutopsyBiochemicalBiologicalCerebral cortexClassClinicalCoenzyme Q10CoenzymesDataDepositionDetectionDevelopmentDiffusionElectron TransportGenerationsGenesGeneticGoalsGrantHigh Pressure Liquid ChromatographyHippocampus (Brain)Huntington DiseaseLeadLinkMass Spectrum AnalysisMeasurementMeasuresMediatingMemoryMusN(6)-(1-iminoethyl)lysineNOS2A geneNeurodegenerative DisordersNeurofibrillary TanglesNeuronsNitrogenNumbersOxidantsOxidative StressParkinson DiseasePathogenesisPatientsPeroxonitritePersonal SatisfactionPropertyReactionReactive Oxygen SpeciesSourceSystemTherapy Clinical TrialsThinkingTissuesTransgenic OrganismsTranslatingVentricularbrain tissuecofactordrug discoveryhuman NOS2A proteinhuman subjectimmunocytochemistryimmunoreactivityimprovedinhibitor/antagonistmild neurocognitive impairmentmouse modelreactive oxygen intermediatetherapy development
项目摘要
DESCRIPTION (provided by applicant): There is increasing evidence that oxidative damage may contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's Disease (AD). A number of recent studies have suggested that oxidative damage may precede and be causally linked to the deposition of beta-amyloid. Conversely, beta-amyloid may induce oxidative damage. There are two major classes of oxidants and biological systems; reactive oxygen intermediates and reactive nitrogen intermediates. A number of studies have shown that there are increased reactive oxygen intermediates in AD postmortem brain tissue as assessed by oxidative damage markers. There also appears to be increased reactive nitrogen intermediates as assessed by biochemical and immunocytochemical measurements of 3-nitrotyrosine. Our data, which has been confirmed by others, shows that there is an increase in inducible nitric oxide synthase (NOS2) immunoreactivity within neurons in both AD postmortem brain tissue, as well as in transgenic mouse models. Genetic reduction of NOS2 activity markedly reduced beta-amyloid deposition in a transgenic mouse model of AD. The goals of the present application are to utilize two compounds, which can block reactive oxygen species and reactive nitrogen intermediates. We will utilize coenzyme Q10 and L-iminoethyl-L-lysine (L-NIL) in transgenic mouse models of AD. CoQ10 is a cofactor of the electron transport gene, which has strong antioxidant properties. It is extremely well tolerated in human subjects and is under clinical development for treatment of Parkinson's Disease, Huntington's Disease and amyotrophic lateral sclerosis. We will also look at the effects of L-iminoethyl-L-lysine, which is a relatively specific inhibitor of NOS2. We will determine whether treatment with either CoQ10 or L-NIL can exert neuroprotective effects against beta-amyloid deposition and oxidative damage, and improve memory in transgenic mouse models of AD. If we can demonstrate significant effects of CoQ10 and L-NIL, this could lead to rapid development of new therapies for slowing the progression of AD.
描述(由申请人提供):越来越多的证据表明氧化损伤可能有助于神经退行性疾病的发病机理,例如阿尔茨海默氏病(AD)。最近的许多研究表明,氧化损伤可能先于与β-淀粉样蛋白的沉积有关。相反,β-淀粉样蛋白可能诱导氧化损伤。有两种主要的氧化剂和生物系统。活性氧中间体和反应性氮中间体。许多研究表明,通过氧化损伤标志物评估,AD尸体后脑组织中的活性氧中间体增加。通过通过3-硝基酪氨酸的生化和免疫细胞化学测量评估,似乎还增加了反应性氮中间体的增加。我们的数据已得到其他证实,它表明,在AD后脑组织脑组织以及转基因小鼠模型中,神经元内神经元内可诱导型一氧化氮合酶(NOS2)的免疫反应增加。在AD的转基因小鼠模型中,NOS2活性的遗传还原显着降低了β-淀粉样蛋白沉积。本应用的目标是利用两种化合物,可以阻断活性氧和反应性氮中间体。我们将在AD的转基因小鼠模型中利用辅酶Q10和L-氨基甲基L-赖氨酸(L-NIL)。 COQ10是电子传输基因的辅助因子,该基因具有强抗氧化特性。它在人类受试者中的耐受性非常好,并且正在临床发展以治疗帕金森氏病,亨廷顿氏病和肌萎缩性侧面硬化症。我们还将研究L-氨基甲基L-赖氨酸的作用,该赖氨酸是NOS2的相对特异性抑制剂。我们将确定用COQ10或L-NIL处理是否可以针对β-淀粉样蛋白沉积和氧化损伤发挥神经保护作用,并改善AD转基因小鼠模型中的记忆力。如果我们能够证明COQ10和L-NIL的显着影响,这可能会导致快速开发新的疗法来减缓AD的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M FLINT BEAL其他文献
M FLINT BEAL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M FLINT BEAL', 18)}}的其他基金
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease
NAD、PGC-1α 和 SIRT3 作为亨廷顿病的治疗靶点
- 批准号:
9197703 - 财政年份:2015
- 资助金额:
$ 16.92万 - 项目类别:
NAD, PGC-1alpha and SIRT3 as Therapeutics Targets for Huntington's Disease
NAD、PGC-1α 和 SIRT3 作为亨廷顿病的治疗靶点
- 批准号:
8888600 - 财政年份:2015
- 资助金额:
$ 16.92万 - 项目类别:
Biomarkers of Oxidative Stress in Parkinson's Disease
帕金森病氧化应激的生物标志物
- 批准号:
7933687 - 财政年份:2009
- 资助金额:
$ 16.92万 - 项目类别:
Biomarkers of Oxidative Stress in Parkinson's Disease
帕金森病氧化应激的生物标志物
- 批准号:
7853567 - 财政年份:2009
- 资助金额:
$ 16.92万 - 项目类别:
Interactions for Pesticides, mitochondria and genetics in Parkinson's disease.
帕金森病中农药、线粒体和遗传学的相互作用。
- 批准号:
7635654 - 财政年份:2009
- 资助金额:
$ 16.92万 - 项目类别:
Mitochondria and Oxidative Stress in Neurodegenerative Disorders
神经退行性疾病中的线粒体和氧化应激
- 批准号:
7327395 - 财政年份:2007
- 资助金额:
$ 16.92万 - 项目类别:
Antioxidant Approaches to Alzheimer's Disease Therapy
阿尔茨海默病治疗的抗氧化方法
- 批准号:
7020246 - 财政年份:2006
- 资助金额:
$ 16.92万 - 项目类别:
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3
辅酶 Q10 对帕金森病 3 期的影响
- 批准号:
6966285 - 财政年份:2005
- 资助金额:
$ 16.92万 - 项目类别:
MITOCHONDRIA AND NEURODEGENERATION IN TRANSGENIC MICE
转基因小鼠的线粒体和神经变性
- 批准号:
6926911 - 财政年份:2005
- 资助金额:
$ 16.92万 - 项目类别:
Effects of Coenzyme Q10 in Parkinson Disease-Phase 3
辅酶 Q10 对帕金森病 3 期的影响
- 批准号:
7614278 - 财政年份:2005
- 资助金额:
$ 16.92万 - 项目类别:
相似海外基金
Oxidative stress-induced vascular pathology and dysfunction in Alzheimer’s disease
阿尔茨海默病中氧化应激诱导的血管病理学和功能障碍
- 批准号:
10523897 - 财政年份:2022
- 资助金额:
$ 16.92万 - 项目类别:
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease
开发减毒呋喃酮作为阿尔茨海默病的新疗法
- 批准号:
10337296 - 财政年份:2018
- 资助金额:
$ 16.92万 - 项目类别:
Defining roles of nitroTyrosine in desease via genetic code expansion
通过遗传密码扩展定义硝基酪氨酸在疾病中的作用
- 批准号:
10641726 - 财政年份:2015
- 资助金额:
$ 16.92万 - 项目类别:
Defining roles of nitroTyrosine in desease via genetic code expansion
通过遗传密码扩展定义硝基酪氨酸在疾病中的作用
- 批准号:
10439859 - 财政年份:2015
- 资助金额:
$ 16.92万 - 项目类别: